Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.

Recruiting N/A Interventional Study
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) Liver Fibrosis/NASH Non-Alcoholic Steato-Hepatitis (NASH)
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
20 – 80
Sex
Any
Study type
Interventional
Purpose
Basic Science
Participants needed
36 (estimated)
Sponsor
Université de Sherbrooke · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis. MASLD results from fat being disproportionately deposited in the liver. The goal of this mechanistic study is to investigate metabolic response in patients aged 20 to 80 years with non…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * aged 20 to 80 years; * diagnosed with MASLD, defined as the presence of liver steatosis + abdominal obesity (as defined by the International Diabetes Federation country/ethnic group-specific criteria; Exclusion Criteria: 1\) Presence of advanced fibrosis using any of the fol…
Contacts

Frédérique Frisch

1-819-346-1110

frederique.frisch@usherbrooke.ca

CONTACT